Navigation Links
Are state Medicaid policies sentencing people with mental illnesses to prison?
Date:7/22/2014

Researchers from the USC Schaeffer Center for Health Policy and Economics have linked tighter Medicaid policies governing antipsychotic drugs with increased incarceration rates for schizophrenic individuals.

The study comes amid media scrutiny over whether cutbacks in mental health actually save money, when other costs are taken into account.

Some health plans require an extra approval step before tests or treatments can be ordered for patients. This step called prior authorization is intended to encourage physicians to select cost-effective options by requiring justification for the selection of more expensive options. Likewise, prior authorization policies adopted by state Medicaid programs aim to reduce costs associated with some medications, especially those drugs used to treat schizophrenia. However, an unintended consequence of these policies may be that more mentally-ill patients are being incarcerated, raising questions about the "cost-effectiveness" of these formulary restrictions.

In a study published today in The American Journal of Managed Care, researchers found that states requiring prior authorization for atypical antipsychotics had less serious mental illness overall but higher shares of inmates with psychotic symptoms than the national average. The study concluded that prior authorization of atypical antipsychotics was associated with a 22 percent increase in the likelihood of imprisonment, compared with the likelihood in a state without such a requirement.

"This paper demonstrates that our policies around schizophrenia may be penny-wise and pound foolish," says Dana Goldman, director of the Leonard D. Schaeffer Center for Health Policy & Economics at the University of Southern California. "Limiting access to effective therapy may save States some Medicaid money in the short run, but the downstream consequences -- including more people in prisons and more criminal activity -- could be a bad deal for society."

The study examined survey data from 16,844 prison inmates in states with and without restrictive authorization requirements overlaid with state Medicaid policies and data as well as usage rates of atypical antipsychotics (a newer drug class that is frequently targeted by prior authorization requirements).

The study's findings come amid a wave of scrutiny surrounding the cost and consequences of failing to adequately provide for mental health care, including the nexus between shortchanging mental health and rising prison expenditures.

"The media has picked up on how incarcerating the mentally ill raises a range of troubling concerns, from the high cost of incarceration, to the inadequate treatment of mentally ill inmates, and the potential for self-inflicted harm among these patients," says Darius Lakdawalla, Quintiles Chair in Pharmaceutical Development and Regulatory Innovation, and a professor at the Schaeffer Center at USC. "At the same time, the American public is increasingly worried about untreated mental illness triggering violent behavior in the community. Our study suggests state Medicaid policies may be part of the solution to these problems."


'/>"/>
Contact: Robert Perkins
perkinsr@usc.edu
213-740-9226
University of Southern California
Source:Eurekalert

Related biology news :

1. Marshall University study may lead to new treatments for prostate cancer
2. Interventional radiology: Potential breakthrough to treat mens enlarged prostate
3. Carnegies Greg Asner named Energy/Climate Fellow by US State Department
4. Planet under Pressure conference, London: Final statement
5. Tokai Pharmaceuticals galeterone well-tolerated in patients with advanced prostate cancer
6. NRC authors brief federal agencies on the state of polar regions
7. Study shows botanical formula fights prostate cancer
8. Ohio state hosts national energy conference
9. New diagnostic tool determines aggressiveness of prostate cancer
10. Syracuse University study finds autumn advantage for invasive plants in eastern United States
11. Experiments may understate plant responses to climate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/13/2017)... 2017 UBM,s Advanced Design and Manufacturing event ... emerging and evolving technology through its 3D Printing and ... alongside the expo portion of the event and feature ... focused on trending topics within 3D printing and smart ... event will take place June 13-15, 2017 at the Jacob ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... 20, 2017  Eli Lilly and Company (NYSE: ... galcanezumab for the prevention of migraine at the American ... place April 22-28, 2017, in Boston ... at AAN, including safety and patient outcomes data for ... a reduction in monthly migraine headache days among patients ...
(Date:4/20/2017)... ... 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology veteran, as ... experience in the learning technologies industry, Mastin joins NetDimensions from the New York office ... (LTG). At LEO, Mastin served as SVP of the North America offices and prior ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader ... announced today that they were named one of the 2017 Top 10 eClinical ... developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one ...
(Date:4/20/2017)... HACKENSACK, N.J. and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell technologies ... Chief Executive Officer, will present at the Alliance for Regenerative ... Investor Day on Thursday, April 27, 2017 at 09:40 EDT ... Dr. Ralph Kern , MD, MHSc, Chief Medical Officer ...
Breaking Biology Technology: